Metabolic-associated fatty liver disease is associated with severity of COVID-19

Yu-Jie Zhou1,2 | Kenneth I. Zheng1 | Xiao-Bo Wang3 | Qing-Feng Sun4 | Ke-Hua Pan5 | Ting-Yao Wang6 | Hong-Lei Ma1 | Yong-Ping Chen1 | Jacob George7 | Ming-Hua Zheng1,8,9

1MAFLD Research Center, Department of Hepatology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China
2Division of Gastroenterology and Hepatology, Key Laboratory of Gastroenterology and Hepatology, Ministry of Health, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai Institute of Digestive Disease, Shanghai, China
3Department of Critical Care Medicine, Wenzhou Central Hospital, Wenzhou, China
4Department of Infectious Diseases, Ruian People’s Hospital, Wenzhou, China
5Department of Radiology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China
6Department of Nephrology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China
7Storr Liver Centre, Westmead Institute for Medical Research, Westmead Hospital and University of Sydney, Sydney, Australia
8Institute of Hepatology, Wenzhou Medical University, Wenzhou, China
9Key Laboratory of Diagnosis and Treatment for The Development of Chronic Liver Disease in Zhejiang Province, Wenzhou, China

Abstract
The Corona Virus Disease 2019 (COVID-19) pandemic has attracted increasing worldwide attention. While metabolic-associated fatty liver disease (MAFLD) affects a quarter of world population, its impact on COVID-19 severity has not been characterized. We identified 55 MAFLD patients with COVID-19, who were 1:1 matched by age, sex and obesity status to non-aged severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-infected patients without MAFLD. Our results demonstrate that in patients aged less than 60 years with COVID-19, MAFLD is associated with an approximately fourfold increase (adjusted odds ratio 4.07, 95% confidence interval 1.20-13.79, P = .02) in the probability for severe disease, after adjusting for confounders. Healthcare professionals caring for patients with COVID-19 need to be aware that there is a positive association between MAFLD and severe illness with COVID-19.
1 | INTRODUCTION

Respiratory disease (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has evolved into a global pandemic. Metabolic-associated fatty liver disease (MAFLD) affects about 20%-30% of people worldwide.\(^1\) However, whether the co-existence of MAFLD affects COVID-19 severity is unknown. We explored the association between MAFLD and COVID-19 severity in non-aged patients with laboratory-proven SARS-CoV-2 infection.

2 | METHODS

The study cohort comprised 55 non-aged patients (<60 years old) with both COVID-19 and MAFLD from three major teaching hospitals (the First Affiliated Hospital of Wenzhou Medical University, Wenzhou Central Hospital and Ruian People’s Hospital) in China. The patients were intended to be matched 1:1 by age (±5 years), sex and obesity status (body mass index ± 1 unit) to non-aged SARS-CoV-2-infected patients without MAFLD. Unfortunately, because of limitations in the number of patients with COVID-19, after matching for age and obesity, there were only 37 males in the non-MAFLD cohort and 45 in the MAFLD cohort (P = .08). All subjects were imaged by computed tomography (CT) for the detection of fatty liver. Detailed information on CT attenuation measurement and diagnosis of fatty liver can be referenced in subsection 1 of the Data S1.

MAFLD was diagnosed according to the recent consensus criteria.\(^1,2\) Detailed diagnostic criteria for MAFLD are described in subsection 2 of the Data S1. Patients with viral hepatitis were excluded; patients with excess alcohol consumption (>20 g/d in females and 30 g/d in males) were excluded to the extent possible according to the clinical notes. Obesity was defined as body mass index (BMI) ≥ 25 kg/m^2 in Asians,\(^3\) and diabetes mellitus was diagnosed according to the history or haemoglobin A1c ≥ 6.5%.\(^4\) Hypertension and dyslipidaemia were diagnosed according to the literature.\(^5,6\)

Briefly, hypertension was defined as blood pressure ≥ 130/85 mmHg or specific drug treatment. Dyslipidaemia was defined as plasma triglycerides ≥ 1.70 mmol/L, or HDL cholesterol < 1.0 mmol/L for men and <1.3 mmol/L for women, or specific drug treatment. Laboratory parameters were measured on the day of admission. COVID-19 severity was assessed during hospitalization and classified into four clinical subtypes (mild, moderate, severe and critical), based on the Chinese management guideline (see subsection 3 of the Data S1). We defined mild and moderate COVID-19 subtypes as ‘non-severe COVID-19’, and severe and critical subtypes as ‘severe COVID-19’. All patients received standard treatments according to the COVID-19 management guidance (7th edition).\(^7\) All patients denied any history of active cancer, coronary heart disease or chronic obstructive or restrictive pulmonary disease. The study was approved by the ethics committees of the three hospitals.

Continuous variables are expressed as mean ± standard deviation or median [interquartile range] and compared using t test or Mann-Whitney U test, as appropriate. Categorical variables were compared using chi-squared test or Fisher exact test for non-ranked variables, and Kruskal-Wallis test for ranked data. Wilcoxon test (paired samples) was utilized to compare values of liver function tests at admission and during hospitalization. The association between MAFLD and severity of COVID-19 was determined by logistic regression. All statistical tests were two-sided and a value of P less than .05 was considered statistically significant. Statistical analyses were performed using SPSS version 22.0 (IBM Corporation).

3 | RESULTS

As shown in Table 1, among 110 non-aged subjects with SARS-CoV-2 infection, no significant difference was observed in age, sex and the proportion of obesity between MAFLD and non-MAFLD groups (all P > .05). Compared with the non-MAFLD group, MAFLD patients had higher levels of C-reactive protein, lactic dehydrogenase, alanine aminotransferase (ALT), aspartate aminotransferase (AST), gamma-glutamyl transferase (GGT), fasting blood glucose and triglycerides (all P < .05). After a median hospital stay of 19.5 days, all cases recovered and were discharged from hospital. The presence of MAFLD was associated with severity of COVID-19 (P = .002), and a trend to increased duration of hospital admission (with an insignificant P value of .09). We then explored impacts of SARS-CoV-2 infection on liver function in 101 patients (49 MAFLD, 52 non-MAFLD) with available information. We compared peak values of aminotransferases, total bilirubin and GGT and minimum albumin value during hospitalization with their corresponding values at admission. We found that ALT, AST, AST/ALT ratio, total bilirubin and GGT were significantly elevated during hospitalization, while the albumin value was significantly decreased during hospitalization compared with that at the time of admission (all P < .001; Table S1).

MAFLD patients comprised 43.7% of non-severe COVID-19 and 73.9% of severe COVID-19 (P = .01). To adjust for confounding variables, we performed multivariable logistic regression analyses (Table 2). The association between MAFLD and the development of severe COVID-19 remained significant after adjusting for age, sex, smoking status, obesity, diabetes and hypertension (adjusted OR 4.07, 95% CI 1.20-13.79, P = .02).

4 | DISCUSSION

Our study demonstrates that in patients less than 60 years of age, the presence of MAFLD is independently associated with severe/critical COVID-19. In China, approximately 80% of deaths from COVID-19 occurred in patients aged 60 years or older.\(^8\) In these patients, other co-morbid conditions including pre-existing respiratory or cardiac disease, and diabetes, may more severely impact the presentation and clinical course of COVID-19. To better define the impact of MAFLD on disease severity, we conducted this research in people aged <60 years.

Previous studies have shown that the angiotensin-converting enzyme 2 (ACE2)/Angiotensin-(1-7)/Mas axis plays a regulatory role in the development of COVID-19, and obesity, diabetes, may more severely impact the presentation and clinical course of COVID-19.
role in insulin resistance and hepatic steatosis, and ACE2 gene expression in liver was increased in people with liver disease compared to those without.\textsuperscript{9,10} However, whether ACE2 expression is elevated in patients with mild to moderate MAFLD compared with healthy controls has not been determined. The spike glycoprotein of SARS-CoV-2 binds to human ACE2 with high affinity, resulting in coronavirus recognition and infection.\textsuperscript{11} This mechanism might possibly explain the association between MAFLD and COVID-19 disease severity. In this study, we found elevations in transaminase values in patients with COVID-19 during hospitalization, suggesting that SARS-CoV-2 infection or the stress of infection and hospitalization can impact liver function, as reported in a previous study.\textsuperscript{12} However, in the context of COVID-19, hepatic and systemic immune and metabolic dysregulation in MAFLD\textsuperscript{13} may exert negative impact on antiviral responses.

Our study has some limitations. Due to the infectious nature of COVID-19 and the emergent situation, fatty liver was detected by CT, rather than the ‘gold standard’ of liver biopsy or magnetic resonance proton density fat fraction (MR-PDFF). However, previous studies report that fatty liver can also be accurately and reliably diagnosed by

| Variable | Overall (n = 110) | Non-MAFLD (n = 55) | MAFLD (n = 55) | P value
| --- | --- | --- | --- | --- |
| Demographics | | | | |
| Age, y | 42.1 ± 11.4 | 40.9 ± 11.9 | 43.4 ± 10.8 | .25 |
| Male, n (%) | 82 (74.5%) | 37 (67.3%) | 45 (81.8%) | .08 |
| Metabolic-associated factors | | | | |
| Body mass index | 25.6 ± 2.9 | 25.0 ± 2.7 | 26.1 ± 3.1 | .07 |
| Obesity, n (%) | 68 (61.8%) | 31 (56.4%) | 37 (67.3%) | .24 |
| Type 2 diabetes, n (%) | 13 (11.8%) | 2 (3.6%) | 11 (20.0%) | .008 |
| Hypertension, n (%) | 24 (21.8%) | 9 (16.4%) | 15 (27.3%) | .17 |
| Dyslipidaemia, n (%) | 68 (61.8%) | 23 (41.8%) | 45 (81.8%) | <.001 |
| Laboratory parameters | | | | |
| White blood cell count, ×10\textsuperscript{9} | 4.9 [3.9, 6.2] | 4.9 [3.9, 6.0] | 4.9 [4.0, 6.5] | .55 |
| Lymphocyte count, ×10\textsuperscript{9} | 1.3 [1, 1.6] | 1.2 [1, 1.6] | 1.3 [1, 1.7] | .57 |
| C-reactive protein, mg/L | 14.9 [3.6, 35.3] | 7.1 [1.1, 24.4] | 21.6 [6.3, 47.5] | .001 |
| ≥10 mg/L, n (%) | 63 (57.3%) | 24 (43.6%) | 39 (70.9%) | .004 |
| Lactic dehydrogenase, U/L | 211.5 [181, 277] | 203 [171, 248] | 232 [196.5, 309.5] | .02 |
| Total bilirubin, μmol/L | 12.4 [9.7, 16.7] | 12.4 [10.1, 16.5] | 12.3 [9.0, 16.7] | .88 |
| Alanine aminotransferase, U/L | 26 [17, 46] | 18 [15, 35] | 29 [24, 54.5] | <.001 |
| Aspartate aminotransferase, U/L | 25.5 [21, 35] | 23 [19, 28] | 31 [22.5, 45] | .001 |
| Alkaline phosphatase, U/L | 58 [50, 73] | 57 [47.5, 75] | 59 [50.5, 69] | .74 |
| Gamma-glutamyl transferase, U/L | 39 [22, 69.5] | 28 [19, 50] | 48 [26, 77] | .002 |
| Fasting blood glucose, mmol/L | 5.5 [5, 6.6] | 5.3 [4.9, 5.9] | 5.7 [5.3, 7] | .003 |
| Triglycerides, mmol/L | 1.2 [1, 1.7] | 1.1 [0.8, 1.6] | 1.5 [1, 1.8] | .01 |
| Total cholesterol, mmol/L | 3.9 [3.3, 4.5] | 4.0 [3.4, 4.5] | 3.8 [3.3, 4.5] | .49 |
| HDL cholesterol, mmol/L | 1.0 [0.9, 1.3] | 1.2 [1, 1.4] | 1.0 [0.9, 1.2] | .001 |
| LDL cholesterol, mmol/L | 2.1 [1.6, 2.8] | 2.1 [1.7, 2.6] | 2.2 [1.5, 3] | .73 |
| Length of hospital stay, days | 19.5 [14, 25] | 18 [13, 21] | 21 [16, 28] | .09 |
| COVID-19 severity, n (%) | | | | |
| Mild | 8 (7.3%) | 7 (12.7%) | 1 (1.8%) | .002 |
| Moderate | 79 (71.8%) | 42 (76.4%) | 37 (67.3%) | |
| Severe | 20 (18.2%) | 5 (9.1%) | 15 (27.3%) | |
| Critical | 3 (2.7%) | 1 (1.8%) | 2 (3.6%) | |

\textsuperscript{#}P value was calculated by comparison between MAFLD and non-MAFLD groups.
TABLE 2  Association between the presence of MAFLD and COVID-19 severity

|                  | OR     | 95% CI            | P     |
|------------------|--------|-------------------|-------|
| Unadjusted       | 3.65   | 1.31-10.16        | .01   |
| Adjusted model I | 3.26   | 1.13-9.38         | .03   |
| Adjusted model II| 4.07   | 1.20-13.79        | .02   |

Note: Data are presented as odds ratios (ORs) and 95% confidence intervals (CIs) measured by univariable and multivariable logistic regression analyses.
Model I: adjusted for age and sex.
Model II: adjusted for age, sex, smoking, obesity, diabetes mellitus and hypertension.

CT scanning. Additionally, although we matched non-MAFLD and MAFLD patients, patients were not matched according to the major outcome and selection bias or other biases might exist. Besides, in our study, COVID-19 severity was assessed during hospitalization, and treatment modalities during hospitalization can impact on the disease status. Moreover, the Asian ethnicity of the cohort, relatively smaller sample size, and the lack of detailed information on medication history might influence the generalizability of the results. Thus, it remains to be established whether the effect we observed of MAFLD on COVID-19 severity can be generalized to other ethnic groups, and whether patients with severe MAFLD (eg MAFLD with significant fibrosis) are more likely to have severe COVID-19 than those with mild MAFLD.

In sum, the results of this preliminary study suggest that the presence of MAFLD in Chinese patients is associated with increased odds of severe SARS-CoV-2 disease. In the context of our results, more care and active monitoring for disease progression are needed for MAFLD patients infected with SARS-CoV-2.

AUTHOR CONTRIBUTIONS
Yu-Jie Zhou and Ming-Hua Zheng involved in concept and design of the study. Xiao-Bo Wang, Qiong-Feng Sun, Ke-Hua Pan, Ting-Yao Wang, Hong-Lei Ma and Yong-Ping Chen involved in data acquisition. Yu-Jie Zhou involved in data analysis and data interpretation. Yu-Jie Zhou and Kenneth I. Zheng drafted the manuscript. Jacob George involved in critical revision of the manuscript for important intellectual content. Ming-Hua Zheng supervised the study. All authors contributed to the manuscript for important intellectual content and approved the submission.

ORCID
Yu-Jie Zhou https://orcid.org/0000-0002-6740-9818
Kenneth I. Zheng https://orcid.org/0000-0002-1726-9298
Ming-Hua Zheng https://orcid.org/0000-0003-4984-2631

REFERENCES
1. Eslam M, Sanyal AJ, George J, et al. MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease. Gastroenterology. 2020;158(7):1999-2014.e1.
2. Eslam M, Newsome PN, Sarin SK, et al. A new definition for metabolic associated fatty liver disease: an international expert consensus statement. J Hepatol. 2020;73(1):202-209.
3. Goda A, Masuyama T. Obesity and overweight in Asian people. Circulation J. 2016;80(12):2425-2426.
4. Sabanayagam C, Khoo EYH, Lye WK, et al. Diagnosis of diabetes mellitus using Hba1c in Asians: relationship between Hba1c and retinopathy in a multiethnic Asian population. J Clin Endocrinol Metabol. 2015;100(2):689-696.
5. Williams B, Mancia G, Spiering W, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J. 2018;39(33):3021-3104.
6. Alberti K, Eckel RH, Grundy SM, et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation. 2009;120(16):1640-1645.
7. National Health Commission & State Administration of Traditional Chinese Medicine. Diagnosis and treatment protocol for novel coronavirus pneumonia (trial version 7). 2020;EB/OL;2020.03.03.
8. [The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19) in China]. Zhonghua liu xing bing xue za zhi. 2020;41(2):145-151.
9. Macédo SMD, Antunes Guimarães T, Feltenberger JD, Santos SHS. Sousa Santos SH. The role of renin-angiotensin system modulation on treatment and prevention of liver diseases. Peptides. 2014;62:189-196.
10. Cao XI, Song L-N, Zhang Y-C, et al. Angiotensin-converting enzyme 2 inhibits endoplasmic reticulum stress-associated pathway to preserve nonalcoholic fatty liver disease. Diabetes Metab Res Rev. 2019;35(4):e3123.
11. Yan R, Zhang Y, Li Y, Xia L, Guo Y, Zhou Q. Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2. Science. 2020;367(6485):1444-1448.
12. Zhang Y, Zheng L, Liu J, Zhao M, Xiao J, Zhao Q. Liver impairment in COVID-19 patients: a retrospective analysis of 115 cases from a single center in Wuhan city, China. Liver Internat. 2020.
13. Narayanan S, Surette FA, Hahn YS. The immune landscape in nonalcoholic steatohepatitis. Immune Netw. 2016;16(3):147-158.
14. Duman DG, Celikci C, Tüney D, İmeryüz N, Avsar E, Tözün N. Computed tomography in nonalcoholic fatty liver disease: a useful tool for hepatosteatosis assessment? Dig Dis Sci. 2006;51(2):346-351.
15. Zeb I, Li D, Nasir K, Katz R, Larijani VN, Budoff MJ. Computed tomography scans in the evaluation of fatty liver disease in a population-based study: the multi-ethnic study of atherosclerosis. Acad Radiol. 2012;19(7):811-818.

SUPPORTING INFORMATION
Additional supporting information may be found online in the Supporting Information section.

How to cite this article: Zhou Y-J, Zheng KI, Wang X-B, et al. Metabolic-associated fatty liver disease is associated with severity of COVID-19. Liver Int. 2020;40:2160-2163. https://doi.org/10.1111/liv.14575